Overview ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study Status: Enrolling by invitation Trial end date: 2029-05-01 Target enrollment: Participant gender: Summary This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Phase: Phase 3 Details Lead Sponsor: ACADIA Pharmaceuticals Inc.